At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed mantle cell lymphoma that is relapsed, refractory, or stable after prior treatment
- ✓Tumor must express cyclin D1 by immunohistochemistry OR harbor t(11;14) translocation by FISH or cytogenetics
- ✓Measurable disease: lymph node/tumor ≥2 cm on imaging, OR palpable splenic enlargement ≥3 cm below left costal margin, OR malignant lymphocytosis (absolute lymphocyte count ≥5000 with monoclonal confirmation by flow cytometry)
- ✓No known CNS involvement (parenchymal mass or leptomeningeal)
- ✕Prior mTOR inhibitor treatment is disqualifying
- ✕No symptomatic congestive heart failure, unstable angina, or cardiac arrhythmia
- ✕No ongoing or active infection
- ✕No known HIV positivity
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of CCI-779 in Combination With Rituximab in Patients With Relapsed or Refractory Mantle Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating rituximab and temsirolimus for Recurrent Mantle Cell Lymphoma. Completed, enrolled 71 participants across 195 sites.
Detailed Summary
This phase II trial is studying how well giving CCI-779 together with rituximab works in treating patients with relapsed or refractory mantle cell lymphoma. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving CCI-779 together with rituximab may kill more cancer cells
Study Details
Timeline
Interventions
375 mg/m\^2 Given IV
25 mg given IV